Drugs / RG-7598
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01432353 | Sep 2011 → Apr 2014 | plasma cell myeloma | Genentech, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RG-7598 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109279 ↗ |
| Known as | DFRF4539A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01432353 ↗ |
| Route | Intravenous | “intravenous DFRF4539A” NCT01432353 ↗ |
| Target | FCRL5 | “Fc receptor-like protein 5 binding agent” CHEMBL2109279 ↗ |